Abstract: In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1? inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1? inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.

Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.

Abstract: Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a ?-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins.

Abstract: Provided are: a compound that thickens or gelatinizes a fluid organic substance to a desired viscosity, or uniformly stabilizes a composition containing the fluid organic substance; a thickening/stabilizing agent including the compound; a thickened/stabilized composition including the thickening/stabilizing agent and a fluid organic substance; and a method for producing a thickened/stabilized composition. The compound according to the present invention is represented by Formula (1): (R2—HNOC)4-n—R1—(CONH—R3)n??(1) where R1 is a group resulting from removing four hydrogen atoms from the structural formula of benzene; R2 and R3 are different from each other and are each independently an aliphatic hydrocarbon group having 6 or more carbon atoms; and n represents an integer of 1 to 3.

Abstract: The present description refers to photocleavable compounds which can be used as a photocleavable linker in order to link two biomolecules, such as oligonucleotides and peptides. The present description further refers to a method for the synthesis of said photocleavable compounds.

Abstract: Compound represented by formula 1: or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: R1 is hydrogen, tert-butoxycarbonyl, where R11 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy, and arrows (?) indicate the position of substituents attachment; R2 is hydrogen, halogen, or C1-C4alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (?) indicate the position of substituents attachment.

Abstract: A polymeric capsule shell of high quality is prepared from an aqueous composition which comprises (A) at least one esterified cellulose ether comprising aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOH, R being a divalent aliphatic or aromatic hydrocarbon group, wherein at least a part of the groups —C(O)—R—COOH are neutralized with an ammonium salt of carbonic acid, formic acid or acetic acid, and (B) from 0 to 7 weight percent of a non-polymeric plasticizer, based on the weight of the esterified cellulose ether, wherein the weight of said at least one esterified cellulose ether is at least 80 percent of the total polymer weight in the aqueous composition.

Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating impaired neurological functions as well as wound and tissue repair.

Abstract: The present invention is related to substituted butanol derivatives of the formula: wherein R is an unsubstituted or substituted C1-6 straight chain alkyl, an unsubstituted or substituted C3-6 branched chain alkyl, an unsubstituted or substituted C3-6 straight chain alkenyl, an unsubstituted or substituted C3-6 branched chain alkenyl, an unsubstituted or substituted C3-6 cycloalkyl, an unsubstituted or substituted C1-6 alkoxy, nitrile, halo, amino, an unsubstituted or substituted C1-6 alkylamino, an unsubstituted or substituted C1-6 dialkylamino, carboxy-C1-6 alkylamino, carboxy-C1-6 dialkylamino, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted C1-6 alkylcarbonyl, an unsubstituted or substituted C1-6 alkylcarboxy, an unsubstituted or substituted C1-6 alkylthio, an unsubstituted or substituted C1-6 alkyloxy, carboxamido, an unsubstituted or substituted C1-6 alkylcarboxamido or an unsubstituted or substituted C1-6 dialkylcarboxa

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A carborane-comprising porphyrin of Formula (1) is provided for use in cancer therapy that extends the period of time between the doses required while the patient is undergoing radiation therapy. The compound can be given not more often than once every 2 or more weeks, avoiding repeated administration, while radiation therapy can continue regularly.

Abstract: The present invention refers to alpha branched alkanoic and alkenoic acids of formula (I) wherein X and R have the same meaning as given in the description. The invention further refers to perfume compositions and fragrance applications comprising them.

Abstract: A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

Abstract: A method for tightening the fat septa of the hypodermis of the eyelids by administering an aqueous solution of citric acid resulting in the reduction of skin tenting, skin sag, lid laxity and skin overhang of the upper and lower eye lids.

Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

Abstract: Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.

Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.